



Please type a plus sign (+) inside this box → +

FEB 18 2005

2/22/05 Rec'd PCT/PTO

18 FEB 2005

PCT

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

	Application Number	10/509,599	
	International Filing Date	March 21, 2003	
	First Named Inventor	Delaney et al.	
	Group Art Unit		
	Examiner Name		
Total Number of Pages in This Submission	6 + refs.	Attorney Docket Number	SMAR-043

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	1. PTO/SB/08A
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	2. Copies of cited references
<input type="checkbox"/> Certified Copy of Priority Documents	<input type="checkbox"/> CD, Number of CD(s)	3. Postcard
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	<input type="checkbox"/> Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Signing Attorney/Agent (Reg. No.)	PAMELA J. SHERWOOD, REG. NO.: 36,677	
Signature		
Date	FEBRUARY 18, 2005	

EXPRESS MAIL LABEL NO.EV577671156US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mail No.

EV577671156US

INFORMATION DISCLOSURE STATEMENT		
Address to:	Attorney Docket	SMAR-043
Commissioner for Patents	First Named Inventor	DELANEY, ALLEN D.
P.O. Box 1450	Application Number	10/509,599
Alexandria, VA 22313-1450	Confirmation No.	
	International Filing Date	March 21, 2003
	Group Art Unit	
	Examiner Name	
	Title:	"CANCER ASSOCIATED PROTEIN KINASES AND THEIR USES"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. § 102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. SMAR-043 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: February 18, 2005

By: Pamela J. Sherwood
Pamela J. Sherwood
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1 of 4

Complete if Known

Application Number	10/509,599
International Filing Date	March 21, 2003
First Named Inventor	DELANEY, Allen D.
Art Unit	
Examiner Name	

Attorney Docket Number

SMAR-043

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	A1	US 2002026226	02-28-2002	Incyte Genomics, Inc.	
	A2	US 2002142953	10-03-2002	Hyseq, Inc.	
	A3	US 2002146692	10-10-2002	Hyseq, Inc.	
	A4	US 2002197679	12-26-2002	Hyseq, Inc.	
	A5	US 2003104529	06-05-2003	Hyseq, Inc.	
	A6	US 2003138793	07-24-2003	IRM LLC	
	A7	US 5,707,829	01-13-1998	Genetics Institute, Inc.	
	A8	US 5,962,232	10-05-1999	Incyte Pharmaceuticals, Inc.	
	A9	US 5,962,312	10-05-1999	Sugen, Inc.	
	A10	US 5,972,676	10-26-1999	Sugen, Inc.	
	A11	US 6,013,500	01-11-2000	The Trustees of Columbia University in the City of New York	
	A12	US 6,124,272	09-26-2000	Isis Pharmaceuticals Inc.	
	A13	US 6,124,272	09-26-2000	Isis Pharmaceuticals Inc.	
	A14	US 6,207,401	03-27-2001	Sugen, Inc.	
	A15	US 6,485,620	10-15-2002	Hyseq, Inc.	
	A16	US 6,500,938B1	12-31-2002	Seilhamer, Jeffrey J., et al.	
	A17	US 6,569,662	05-27-2003	Hyseq, Inc.	
	A18	US 6,586,390	07-01-2003	Hyseq, Inc.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				
	B1	WO	00/6728 ✓ A	02-10-2000	Incyte Pharmer Inc.		
	B2	WO	01/53312 ✓ A	07-26-2001	Hyseq, Inc.		
	B3	WO	01/81555 ✓ A	11-01-2001	Incyte Genomics inc.		
	B4	WO	02/01357 ✓ A	12-19-2002	IRM LLC		
	B5	WO	97/02357 ✓	01-23-1997	Affymetrix, Inc.		
	B6	WO	01/36602 ✓	05-25-2001	Pharmacia and Upjohn S.P.A.		
	B7	WO	99/53036 ✓	10-21-1999	Sugen, Inc.		
	B8	WO	00/56864 ✓	09-28-2000	University of Dundee		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
				Application Number	10/509,599
				International Filing Date	March 21, 2003
				First Named Inventor	DELANEY, Alien D.
				Art Unit	
				Examiner Name	
Sheet	2	of	4	Attorney Docket Number	SMAR-043

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴				
	B9	WO	00/73469A3	12-07-2000	Sugen, Inc.		
	B10	WO	01/42467 ✓	06-14-2001	Millenium Predictive Medicine, Inc.		
	B11	WO	01/44497 ✕	06-21-2001	University of Dundee		
	B12	WO	01/57058 ✓	08-09-2001	Metagen Gesellschaft Fur Genomforschung MBH		
	B13	WO	01/77389 ✓	10-18-2001	Incyte Genomics, Inc.		
	B14	WO	02/29103 ✓	04-11-2002	Gene Logic, Inc.		
	B15	WO	92/19258 ✕	11-12-1992	Childrens Hospital of Los Angeles		
	B16	WO	97/22702 ✓	06-27-1997	Sugen, Inc.		
	B17	WO	98/41638 ✓	09-24-1998	Medical Research Council		
	B18	WO	99/37788 ✓	07-29-1999	Sugen, Inc.		
	B19	WO	99/63073 ✕	10-09-1999	The Trustees of Columbia University in the City of New York		
	B20	WO	99/64576 ✓	12-16-1999	Bayer Corporation		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
(use as many sheets as necessary)				International Filing Date	March 21, 2003
				First Named Inventor	DELANEY, Allen D.
				Art Unit	
				Examiner Name	
Sheet	3	of	4	Attorney Docket Number	SMAR-043

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	C1	ABO, A., et al. "PAK4, a novel effector Cdc42Hs, is implicated in the reorganization of the actin cytoskeleton and in the formation of filopodia". EMBO Journal, (1998), 17(22):6527-40		
	C2	ALESSI, D.R., James, S.R. and Downs, C.P., et al. "Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balph", Curr Biol (1997) 7(4):261-9		
	C3	CROSS, T.G., et al. "Serine/threonine protein kinases and apoptosis". Exp Cell Res, (2000), 256(1):34-41		
	C4	DREWES, G., et al. "MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption". Cell (1997), 89(2):297-308		
	C5	DUESTERHOEFT, A. and Lauber, J. and Mewes, H.W., et al. MIPS A.M. Klopferspitz 18a, D-82152 Martinsried Germany Genbank Submission		
	C6	HAYASHI, A., et al. "PKCnu, a new member of the protein kinase C family, composed fourth subfamily with PKCmu". Biochim Biophys Acta (1999) 1450(1):99-106		
	C7	JOHANNES, F.J., et al. "PKCu is a novel, atypical member of the protein kinase C family". J Biol Chem (1994), 269(8):6140-8		
	C8	KANDLI, M., et al. "Isolation and characterization of two evolutionarily conserved murine kinases (Nek6 and nek7) related to the fungal mitotic regulator, NIMA". Genomics (2000), 68(2):187-96		
	C9	KIMURA, M., et al. "Cell cycle-dependent expression and spindle pole localization of novel human protein kinase, Aik, related to Aurora of Drosophila and yeast Ipl1". J Biol Chem (1997) 272(21):13766-7		
	C10	KIMURA, M., et al. "Assignment of STK6 to human chromosome 20q13.2->113.3 and a pseudogene STK6P to 1q41-.q42". Cytogenet Cell Genet (1997), 79(3-4):201-3		
	C11	KO, T.K., et al. "CrkRS: a novel conserved Cdc2-related protein kinase that colocalises with SC35 speckles". J Cell Sci, (2001), 114(Pt 14):2591-2603		
	C12	KOLOBOVA, E., et al. "Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites". Biochem J (2001), 358(Part I): 69-77		
	C13	LAZZARO, M.A., et al. "A novel cdc2-related protein kinase expressed in the nervous system". J. Neurochem, (1997), 69(1):348-64		
	C14	MADAULE, P., et al. "Role of citron kinase as a target of the small GTPase Rho in cytoskeletons". Nature (1998) 394(6692):491-4		

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
(use as many sheets as necessary)				International Filing Date	March 21, 2003
				First Named Inventor	DELANEY, Allen D.
				Art Unit	
				Examiner Name	
Sheet	4	of	4	Attorney Docket Number	SMAR-043

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	C15	MEYERSON, M., et al. "A family of human cdc2-relatd protein kinases". EMBO Journal, (1992), 11(8):2909-2917		
	C16	NAGASE, T., Ishikawa, A. and Suyama, M., et al. "Prediction o the coding sequences of unidentified human genes. ZII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro". DNA Res (1998) 5(6):355-364		
	C17	OKUDA, T., et al. "Cloning of genomic loci and chromosomal localization of the human PCTAIRE-1 and -3 protein kinase genes". Genomics (1994), 21(1):217-221		
	C18	PINES, J.N. and Kelly, E. CDC2-related protein kinase 7 [homosapiens] DB Source Refsec: accession NM_016507.1		
	C19	PULLEN, N., et al. "Phosphorylation and activation of p70s6k by PDK1". Science (1998), 279(5351):707-10		
	C20	QIU, Y., et al. "Signaling network of the Btk family kinases". Oncogene (2000),19:5651-61		
	C21	SILICIANO, J.D., et al. "itk, a T-cell-specific tyrosine kinase gene inducible by interleukin 2". PNAS USA (1992), 89(23):11194-8		
	C22	WAMBUTT, I., Heubner, D. and Mewes, H.W., et al. Direct submission to Genbank submitted March 10, 1999. MIPS Accession No. AL050147		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.